Skip to main content
. 2021 Feb 1;117(7):1746–1759. doi: 10.1093/cvr/cvab024

Table 1.

Patient characteristics

Characteristics Ctl (non-obese) Obese
Patients, n 6 9
Male gender, n (%) 4 (80) 6 (67)
Age (years), mean±SD 73 ± 6 71 ± 5
BMI (kg/m2), mean±SD 25 ± 1 34 ± 2*
CAD, n (%) 0 (0) 4 (44)
AVD/MVD, n (%) 2 (33) 3 (33)
CAD+AVD/MVD, n (%) 4 (67) 2 (22)
Hypertension, n (%) 5 (83) 5 (55)
Hyperlipidemia, n (%) 3 (50) 8 (89)*
LA diameter (mm), mean±SD 47 ± 1 45 ± 8
LVEF (%), mean±SDa 60 ± 6a 56 ± 9a
Oral antidiabetic drugs, n (%)b 0 (0) 8 (89)*
Insulin, n (%) 0 (0) 8 (89)*
ACEI/ARB, n (%) 5 (83) 6 (67)
Beta blockers, n (%) 1 (17) 6 (67)
Calcium channel blockers, n (%) 0 (0) 1 (11)
Digitalis glycosides, n (%) 0 (0) 0 (0)
Diuretics, n (%) 1 (17) 5 (55)
Lipid-lowering drugs, n (%) 3 (50) 7 (78)
Oral anticoagulants, n (%) 0 (0) 0 (0)
Nitrates, n (%) 0 (0) 0 (0)
Platelet inhibitors, n (%) 3 (50) 8 (89)
CRP (mg/dL), mean±SD 0.75 ± 0.6 0.67 ± 0.52
Leucocytes (/nL), mean±SD 7.8 ± 1.4 8.7 ± 2.6

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; AVD, aortic valve disease; BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; LA, left atrial; LV, left ventricular; MI, myocardial infarction; MVD, mitral valve disease; SD, standard deviation.

*

P < 0.05 determined by Wilcoxon rank sum test for continuous variables, and Fisher’s exact test for categorical values.

a

Data missing from n = 2 Control and n = 4 Obese patients.

b

Metformin (n = 3), Sitagliptin (n = 3), Glibenclamide (n = 1), Dapagliflozin (n = 1).